文献速递临床试验与 GCP基础与转化研究

左束支区域起搏与右室起搏治疗房室传导阻滞且左室功能保留患者的随机临床试验

Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-10-28

LEAP-Block 多中心随机对照试验纳入 499 例房室传导阻滞且 LVEF≥50%、预期心室起搏比例>40% 的患者,比较左束支区域起搏(LBBAP)与右室起搏(RVP)24 个月临床结局。

要点

  • LBBAP 较 RVP 降低 24 个月复合终点风险,绝对风险差 -10.1%。
  • LBBAP 组心衰事件更少,绝对风险差 -7.9%。
  • 急性手术成功率与器械相关并发症两组无显著差异。

核心结论

  • 在房室传导阻滞且 LVEF 保留、需高负荷心室起搏的患者中,LBBAP 在降低 24 个月全因死亡、心衰事件或升级双心室起搏复合终点方面优于 RVP。

研究设计与样本

  • LEAP-Block 为前瞻性、多中心、随机、对照、优效性试验,在中国 14 家医院开展,2021 年 1 月至 2025 年 8 月,末次随访 2025 年 6 月 3 日。
  • 551 例 LVEF≥50% 需心室起搏者接受资格评估,499 例预期心室起搏>40% 者按 1:1 随机至 LBBAP(n=249)或 RVP(n=250)。
  • 主要分析纳入 482 例(LBBAP n=242,RVP n=240;平均年龄 67 岁;女性 46%)。

主要发现

  • 心衰事件 LBBAP 3.4% vs RVP 11.3%,绝对风险差 -7.9%(95%CI -13.0% 至 -2.8%)。
  • 全因死亡、升级双心室起搏、器械相关并发症及起搏诱导心肌病两组无显著差异。

关键数值与推荐

  • 心衰事件绝对风险差 -7.9%(95%CI -13.0% 至 -2.8%)。

临床怎么用

  • 对于房室传导阻滞且 LVEF≥50%、预期高负荷心室起搏的患者,LBBAP 可作为优于 RVP 的起搏策略以减少复合终点事件。
  • LBBAP 急性手术成功率与 RVP 相当,左束支捕获确认率 79.7%,器械相关并发症无显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with atrioventricular block requiring high-burden ventricular pacing, the optimal pacing strategy to reduce heart failure (HF) and all-cause mortality remains uncertain. Robust comparative evidence on the clinical outcomes of left bundle-branch area pacing (LBBAP) vs right ventricular pacing (RVP) in this population is needed. OBJECTIVE: To compare 24-month clinical outcomes of LBBAP vs RVP in patients with atrioventricular block and preserved left ventricular ejection fraction (LVEF; ≥50%). DESIGN, SETTING, AND PARTICIPANTS: The LEAP-Block study was a prospective, multicenter, randomized, controlled, superiority trial conducted across 14 Chinese hospitals from January 2021 to August 2025, with last follow-up on June 3, 2025. Of 551 patients with LVEF 50% or greater requiring ventricular pacing who underwent eligibility assessment, 499 with anticipated ventricular pacing greater than 40% were randomized. INTERVENTIONS: Patients were randomized in a 1:1 ratio to LBBAP (n = 249) or RVP (n = 250). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of all-cause death, HF events, or upgrade to biventricular pacing at 24 months. Secondary end points included pacing-induced cardiomyopathy and device-related complications. RESULTS: The primary analysis included 482 patients (LBBAP, n = 242; RVP, n = 240; mean age, 67 years; 46% female). Acute procedure success was comparable between the 2 groups (LBBAP, 237/242 [97.9%] vs RVP, 239/240 [99.6%]; P = .22), with left bundle-branch capture confirmed in 188 of 236 patients (79.7%). LBBAP significantly reduced the primary end point vs RVP (2.4% vs 12.5%, respectively; absolute risk difference, -10.1% [95% CI, -16.8% to -3.4%]; P = .003). Among secondary outcomes, the LBBAP group had fewer HF events (3.4% vs 11.3%; -7.9% [95% CI, -13.0% to -2.8%]). No significant differences were observed in all-cause death, biventricular pacing upgrade, device-related complications, or pacing-induced cardiomyopathy. The 24-month Kaplan-Meier estimated cumulative incidence of the primary end point was 5.0% for LBBAP vs 13.2% for RVP (hazard ratio, 0.37 [95% CI, 0.19 to 0.73]; P = .004). LBBAP superiority was consistent across all prespecified subgroups. CONCLUSIONS AND RELEVANCE: Among patients with atrioventricular block and preserved LVEF requiring high-burden ventricular pacing, LBBAP was superior to RVP in reducing the risk of the composite end point of all-cause death, HF events, or upgrade to biventricular pacing at 24 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04730921.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Li X, Wang H, Zhang W, et al. Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial. JAMA. 2026. PMID: 42949742. doi:10.1001/jama.2026.18146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。